Information on the stock exchange trading

Please be advised that procedures connected with admission of Bioceltix S.A. shares to stock exchange trading are currently being finalized. Application for admission to trading covers series A, B, C, D, F and G shares – marked with ISIN code PLBCLTX00019. Registration of the shares depends on the resolution of the Warsaw Stock Exchange on […]

Economic Forum in Karpacz

Łukasz Bzdzion, President of the Management Board, participated in the XXX Economic Forum in Karpacz on behalf of Bioceltix. The second day of the conference began with a business breakfast organized as part of Innovation Rocket – a project that is part of the wider Economic Accelerator program, aimed at supporting the development and internationalization […]

Bioceltix begins the next phase of research

We made the next important step on the way to the registration of our drug candidates in the European Medicines Agency. The next phase of research has started for our two medicinal products: BCX-CM-J – a drug candidate for the treatment of degenerative joint lesions and BCX-CM-AD – a drug candidate for the treatment of […]

Increasing the company’s share capital

In connection with the issue of series G shares, on April 23, 2021, an increase in the share capital was registered. All formalities related to our IPO are being proceeded according to the plan. We are currently waiting for the admission of shares in Bioceltix S.A. for trading. In the near future, shares are to […]

Puls Biznesu investor chat

On 02/03/2021 there was an investor chat with our participation. We invite you to watch the chat here: https://www.pb.pl/czat-inwestorski-ze-spolka-bioceltix-akcja-inwestor-1109458

The Innovation Station in our office

The Innovation Station is a broadcast that presents projects and products of Polish authors. We have also been included among them when we talked in one of the episodes about what we do, how we do it and for whom. Of course, the key theme of the meeting were stem cells and their application in […]

The 24th edition of Wall Street conference – an online event

The Wall Street conference, i.e. the most important event in the Polish capital market, was held between 25 and 27 November 2020. This time it was organized on-line. The conference is a meeting place for individual investors and capital market-related entities. Tens of lectures by best domestic experts, panel discussions and economic debates are held […]

Bioceltix received a permit for the production of a veterinary medicinal product

On October 5, 2020, we received a long-awaited permit from the Main Pharmaceutical Inspectorate for the production of a veterinary medicinal product of cell therapy, which is an important milestone in the development of our company. Obtaining the permit ranks us among the few companies in the world with production facilities that meet the requirements […]

Bioceltix to debut on NewConnect

Since its establishment, Bioceltix has already raised several million USD from private investors and public grants. Shareholders believe in our vision – as one of the first companies in the world, we plan to go through the full authorization procedure with the European Medicines Agency for a veterinary medicinal product using stem cells as active […]

Bioceltix joins the Warsaw Stock Exchange Academy

Members of Bioceltix Management Board have decided to take part in the Warsaw Stock Exchange Growth Academy. This is the second edition of the program organized by the WSE. It aims to build the competences of leaders who want to take their business to the next level. We believe that our participation in the workshops […]

We have joined the Polish Association of Producers and Importers of Veterinary Medicines „POLPROWET” as an observer member.

The Polish Association of Producers and Importers of Veterinary Medicines „POLPROWET” represents importers, producers and exclusive distributors of veterinary medicines in Poland. The veterinary pharmaceutical industry aims to provide high-quality food of animal origin and contributes to the economic growth of the country by caring for the protection of the natural environment. Polprowet represents the […]

Bioceltix: Year in Review

2019? It’s been a good year for Bioceltix. A victory in the Start-Up Challenge coupled with participation in accelerator programs as well as several important congresses, conferences and rankings. A lot has happened over the past year and the next 12 months look even more exciting. Want to know what Łukasz Bzdzion thinks of the […]

Start-ups in the Palace

’Start-ups in the Palace’ is an event the main theme of which deals with the cross-border expansion of Polish startups. It is being organized in cooperation with Polish Investment and Trade Agency (PAIH) at the Presidential Palace in Warsaw. We couldn’t miss this opportunity especially given the host – President Andrzej Duda! The project includes […]

„InCradibles” finalists in London

As part of the workshops organized by Incredibles in the UK’s capital city we had a chance to get together with business mentors. True to its name the experience provided an „incredible” dose inspiration and knowledge. Special Thanks to: Marta Krupińska (Head of Google For Startups UK), Mariama Boumanjal (GFS Program Manager), Stijn Tops (Google […]

MamStartup: Innovative veterinary therapies

Mamstartup: Gallant has developed a non invasive method for retrieving stem cells which can be used to treat various ailments – from torn ligaments and joint inflammation to kidney disease. Poles have accomplishments when it comes to utilizing stem cells in animal treatment. PLN 5.1 million – that’s how much the biotech company Bioceltix received […]

A Polish startup wants to improve the way we fight diseases in dogs and cats

Business Insider caught up with Łukasz Bzdzion, founder of the startup Bioceltix, who – together with his team – is developing biopharmaceuticals for dogs, cats and horses. How is his company improving treatments for animals suffering from degenerative joint or autoimmune diseases? Find out in the article below!

Business Insider Trends Festival 2019 and Bioceltix

Trends Festival? We had to be there! It’s the most important event for the business community organized by Business Insider Polska. An interactive festival featuring business trends, art and inspiration – there’s also a chance to network with international experts from your industry. Łukasz Bzdzion was taking part in a mentoring workshop being organized as […]

My Company Polska: Bioceltix among the 25 best Polish startups

My Company Polska has selected the 25 hottest and best startups – and we’re among them! The stem-cell-based pharmaceuticals, which Bioceltix is developing, are a safer and more effective alternative to traditional chemical-based pharmaceuticals currently on the market. Bioceltix was established in 2016 – with its first funding coming from the StartitFund which is managed […]

Rzeczpospolita: Millions for Polish medicine for horses

Rzczpospolita: The Wroclaw-based biotech, which is working on breakthrough biopharmaceuticals intended for animals, has received additional financing in the amount of 5.1M PLN. Thanks to the grant Bioceltix, a startup, will begin working on a new project aimed at developing a stem-cell-based treatment for horses. More.

We’re looking an R&D Specialist

We’re looking to expand and are in search of a new team member. Who is it that we’re looking for? An R&D Specialist. This person should have a degree in biology, biotechnology, pharmacology, medicine or related fields. He/she should also have experience related to aseptic cell-culture techniques. We are looking for an expert with basic […]

NCBR focuses on modern medicine

In the years to come, we are going to see a crop of biotechnology and other projects with global potential. Breakthrough innovations will not happen by accident but will rather result from a pre-programmed process, supported, among others, by the National Centre for Research and Development under the “Fast Track” scheme. Indeed, Bioceltix, a start-up […]

Parkiet: Bioceltix. A Wrocław startup thinks about the stock market

Parkiet: Bioceltix has been developing its own pharmaceuticals since 2016. It is also one of the first companies in Europe to complete a full EMA registration path for a medicinal product that uses mesenchymal stem cells (MSC) as an active substance. The therapies created by Bioceltix are supposed to be a safer alternative to current […]

VetHealth Global 2019

We are in Canada at the VetHealth Global 2019! Every two years, senior executives, emerging companies, investors, regulators, and researchers from around the world gather in Charlottetown, Prince Edward Island, Canada to explore market trends, global regulatory issues, and innovative developments related to companion and food animal health and nutrition.

PFR BioMed Academy: Bioceltix

We’re excited to announced that we are officially „enrolled” in the PFR BioMed Academy – an educational program designed specifically for innovative companies doing business in the #pharmaceutical and medical industries. Thank you for this awesome form of recognition!

InCredibles: Bioceltix

Our company is one of six to qualify for InCredibles 2019 being organized by Sebastian Kulczyk. Incredibles is a multi-purpose program that combines an accelerator with mentoring and support for up-and-coming Polish companies from the tech industry. – We place an emphasis on the practical aspect related to creating and running a business. This is […]

Most Creative People in Business #stories | Łukasz Bzdzion – Bioceltix

A year ago, Łukasz Bzdzion, CEO of Bioceltix, was second in the prestigious „Most Creative People in Business” ranking. Today, as the latest edition of the ranking is published, we get introduced to a new lineup of business leaders. We’re keeping our fingers crossed and hope you are too…and while you do that, why not […]

Start with innovations: stem cells in animal treatment 

Radio dla Ciebie: Yesterday (May 27) Łukasz Bzdzion from Bioceltix – the biotech startup that was recently recognized during European Startup Day organized as part of the European Economic Congress in Katowice – talked about utilizing stem cells to treat osteoarthritis in animals. Bioceltix has a chance to become one of the first companies in the world, […]

Bioceltix at Impact’19 in Cracow!

Cracow Tech Week, is a side activity of Impact’19! It’s a celebration of tomorrow’s technologies and talent – the place to be if you want to meet and interact with enthusiasts from all walks of the digital world. There, on one of the startup stages, Paweł Wielgus talked about the solutions being developed by Bioceltix […]

Bioceltix wins Start-Up Challenge contest!

On Tuesday (May 14th), during European Startup Days, as part of the 11th European Economic Congress in Katowice, promising startups were recognized and awards handed out! The winner in the in the „medicine, healthcare, medical technology, pharmaceuticals and biotech category” was Bioceltix. The jury recognized their ambitious clinical research plan, developed business model and scaling […]

A revolution in veterinary care that’s made in Poland

Money: Scientists from Wroclaw are working on breakthrough drugs for dogs, horses and cats. They are being supported by experienced investors. The objective is clear: Bioceltix wants to become one of the first companies in the world to register it’s stem-cell-based biopharmaceutical with the European Medicines Agency (EMA).  – the market for veterinary biopharmaceuticals is […]

We’ve made it to the finals of the Start-up Challenge!

Ideas that use pioneering solutions? Artificial intelligence, biological drugs, new applications…? Yes! The European Start-up Days are about to begin, so we are looking forward to 14 May. We are also happy to announce that we are among 18 shortlisted finalists of the Start-up Challenge competition. This year, a record number of nearly 300 start-ups from several continents […]

The 8th Meet-up TOP500 Innovators & PAMI and Bioceltix

There are only few days left to the 8th Meet-up TOP500 Innovators & PAMI. A panel discussion will be an opportunity to listen to Łukasz Bzdzion, Bioceltix CEO, Michał Wronecki from Bioavlee S.A., Filip Jelen, PhD, MBA (Pure Biologics and Captor Therapeutics) and Olga Grudniak from Biolumo. We hope to see you soon!

Bioceltix is taking seminars by storm!

Intense workshops and seminars, that’s what we like best! Łukasz Bzdzion, CEO of Bioceltix,  Is currently finishing up an updated presentation of our company and we can wait to see the finished product. Also, we’re currently running up our public speaking skills. 

Bioceltix has the power to change the world

Many biotech startups are spending money from investors and grants by the billions, in an effort to find new ways of treating humans, but some of them have chosen to focus their attention on animals. Bioceltix does business on this developing market of veterinary products. Developing innovative biopharmaceuticals designed to treat ailments commonly experienced by […]

Renovation work – completed

We have completed renovation work at our R&D centre. We launched new laboratories and we are back to business as usual. A dedicated modular system of an isolated process line for growing animal stem cells of a pharmaceutical standard is now entering the final test stage. For those interested in our accomplishment: see the before […]

Five life science start-ups that can change the world

We have found ourselves in the ranking of the 5 most promising Polish start-ups prepared by Money.pl! “From those looking for a drug to cure cancer, through manufacturers of at-home lab devices, up to scientists who want to set stem cells to save the lives of animals. Poland seems to be swarming with biotech and telemedicine […]

Łukasz Bzdzion on Radio Wrocław

Łukasz Bzdzion visited Filip Marczyński on Radio Wrocław. The CEO of Bioceltix talked about biological drugs for animals that are currently developed with the use of mesenchymal stem cells, and also about the entire team’s plans for the nearest future. You can listen to the full interview here.

Veterinary biological drugs – Bioceltix summarizes the year 2018

For Bioceltix, last year was filled with new, exciting challenges. From rankings and accelerator programs to contests and even a newly-opened #lab – it’s been a busy time. The ultimate goal remains unchanged – launching innovative biopharmaceuticals for #animals… and we’re getting closer by the day. Read more about what our company has been up […]

The Chivas Venture finale

The final of the Chivas Ventures contest took place last week. We are extremely happy to have had the opportunity to meet some many creative people in this „final of finals” – each of them with exactly the same purpose – making the world a better place. Each year, this competition brings together entrepreneurs who’s […]

MIT Enterprise Forum Poland: DemoDay

On Tuesday (8th January) startups participating in the MIT Enterprise Forum Poland competition had a chance to present their innovative technologies to representatives of corporations, big business and investment funds. This meeting also marked the official conclusion of the 5th edition MIT EF Poland program. MIT EF Poland – thank you!

Merry Christmas and happy New Year!

On behalf of the entire Bioceltix team, we would like to wish you a very successful, healthy and joyful New Year. We look forward to our work together in 2019.

Bioceltix is ​​working on drugs based on stem cells for animals [interview]

MamStartup: Bioceltix is a biotech startup that does business in the veterinary industry – the company focuses on developing stem-cell-based biopharmaceuticals.  These biopharmaceuticals are a safer as well as more effective alternative to synthetic drugs, which treat only symptoms, not underlying causes. The aforementioned „synthetics” still remain by far the most popular choice when it […]

Innowacje na start: Chivas Venture and Bioceltix

We hope you had a chance to tune in to „Radio dla Ciebie” during the „Let’s start with Innovation” („Innowacje na start”) show – that’s for coverage of Chivas Ventures. The forth edition of this contest for startups that are socially involved has now come, gone and guess what? The jury liked our biopharmaceutical veterinary […]

Bioceltix has made it to the final round of Chivas Ventures

Another round of the prestigious contest designed for social-involved startups – Chivas Venture–  is behind us. We are among the five companies that, on January 17th 2019, will take part in the grand finale of the contest – which is happening in Warsaw. That mid-January evening will be when we find out which innovative company […]

Chivas Venture and Bioceltix? YES!

The jury has spoken… and unveiled their list of finalists in the forth edition of Chivas Venture contest designed for startups that are socially engaged. They had over 100 entries to choose from…a big reason why we are so excited that Bioceltix was one of just 11 companies that advanced to the final round. Next […]

(Un)limited stem cells

biotechnologia.pl: Poland is among the countries where innovative biopharmaceuticals re being designed to treat household animals. Bioceltix is developing MSC-based medicines for dogs, horses and cats. The biopharmaceuticals, which are made in Poland, utilise the anti-inflammatory and pain-relief properties of Mesenchymal Stem Cells. In contrast to traditional chemical-based pharmaceuticals, the bio-based variants being developed by […]

We’ve begun the process of accelerating thanks to MIT Enterprise Forum Poland

We are one of 18 innovative companies taking part in the 5th edition of MIT Enterprise Forum Poland accelerator program. There are three months of hard work and immense, new challenges ahead. If we are lucky enough to be among those who are selected to move on, our next stop is Boston Massachusetts,, USA, where […]

More startups participating in the MIT Enterprise Forum Poland accelerator program. The technologies they have to offer are full of surprises!

proseedmag: the MIT Enterprise Forum Poland program aims to speed up the development of recently-established tech companies. It accomplishes this by connecting these innovators with the know-how, experience and assets of leading corporations, investment funds as well as various other organizations from Poland and around the world. Nearly 100 startups have already received a much-needed […]

Bioceltix is entering an infant industry

All of the stem-cell-based biopharmaceuticals being developed by our company are designed to treat conditions caused by chronic inflammatory diseases. We are developing biopharmaceuticals to treat osteoporosis and atopic dermatitis in dogs, chronic inflammation of the oral cavity as well as gingivitis in cats, and medicines that help heal torn ligaments and treat conditions related […]

We are modernizing our lab

All hands on deck! Our research and development center is hard at work! Karol Wrzeszcz, our quality control expert, is supervising the job and keeping an eye on… safety. At Bioceltix, Karol is responsible for implementation and day-to-day operation of the Pharmaceutical Quality System. Construction of our new production facility that meets CGMP standards is […]

The 2nd phase of MIT EF Poland

The 2nd phase of MIT Enterprise Forum Poland took place at Adamed headquarters on Friday (24 August). During the meeting Paweł Wielgus, a member of our company’s management board, presented treatments for the most popular animal diseases and discussed plans related to the launch of biopharmaceuticals based on mesenchymal stem cells.  

We know the results of the 50 Most Creative Minds in Business ranking

The gala that concluded the 8th edition of this ranking took place on June 27th at Warsaw’s Multikino Złote Tarasy. This time the event was conducted in an entirely new format. It was hosted by Grzegorz Kiszluk, Editor-in-Chief of Brief Magazine as well as award winners from previous years. Łukasz Bzdzion, CEO of our very […]

We’ve moved on to the next phase of MIT Enterprise Poland

On Friday, August 24th, as part of our involvement in the accelerator program organized by MIT Poland, we are participating in a meeting during which we will be able to present our accomplishments to-date and share our plans related to the launch of veterinary  biopharmaceuticals. The next phase of MIT EF will take place in […]

Bioceltix – Wroclaw start-up awarded. Creates biological drugs for animals

Gazeta Wrocławska: Bioceltix develops biological drugs for common pet diseases. At the moment, the company is working on drugs for locomotor system diseases (osteoarthritis), autoimmune diseases (atopic dermatitis) and various types of cancer. – The products that we create use the analgesic and anti-inflammatory properties of mesenchymal stem cells, which makes them a modern alternative to […]

Residents of Wroclaw are among the most creative contributors to business in 2018

Scientists, experts and entrepreneurs from Wroclaw have been recognized in the Most Creative Minds in Business Ranking published by Brief magazine. As high as second on the prestigious list was Łukasz Bzdzion – the biotechnologist and molecular biologist who is the founder and CEO of Wroclaw-based biotech startup Bioceltix. His company is focused on developing […]

Animals in a medical revolution

Wrocław scientists in the comfort of laboratories are preparing drugs that change the standards of treating dogs, cats and horses. Just a little bit of fat, a lot of capital and a dose of scientific magic – it’s the Puls Biznesu about us! Read more.

Łukasz Bzdzion on the podium!

The Jury of the 8th edition of The 50 Most Creative in Business ranking has decided – Łukasz Bzdzion, Bioceltix CEO, took the second place. The founder of Bioceltix noted that already every fifth dog experiences suffering associated with degenerative joint changes. Our company combines imagination with scientific knowledge, due to which we create a safe and […]

The Polish startup creates super modern drugs for animals

As the first company in Europe, Bioceltix intends to authorize a veterinary biopharmaceutical based on stem cells. Łukasz Bzdzion, the CEO of the startup we talked to at the Impact’18 congress, tells about the advantages of Polish technology over those that are currently in use – Business Insdier Polska.

Interview with Łukasz Bzdzion on Impact’18 in Kraków

We was on Impact’18, congress that brings leaders at the forefront of innovation from many sectors together to explore the opportunities for creating global biotechnology future. ImpactCEE is the most important event on the future of the biotechnology and digital economy for the business, startups, scientists and public officials.

WallStreet 22 Conference: Łukasz Bzdzion

CEO of Bioceltix, Łukasz Bzdzion, during the WallStreet conference in Karpacz talked about the AlloMSCs technology, biopharmaceuticals based on stem cells and business model of our company.

Bioceltix among The 50 Most Creative in Business

Ranking The 50 Most Creative in Business is an initiative that for 7 years has been helping to build and promote the innovative and creative business segment in Poland. The Jury of the 8th edition of the 50th Most Creative in Business decided that Bioceltix should be among 50 this year’s winners. The gala of […]

The Polish company has created innovative veterinary drugs

– We are the first company in Europe to develop and implement animal-safe and business-scale technology that uses allogeneic stem cells in therapy. Thanks to the use of allogeneic cells, i.e. one donor and many recipients, we have the opportunity to create drugs that will be available immediately, at the clinic, at the veterinarian – […]

Łukasz Bzdzion – the WOW effect from Poland

Founder and President of Bioceltix is of two natures – the one of an experienced scientist and the one of an entrepreneur, subjecting medical innovations in the veterinary science to commercialisation. On dyskusja.biz, Łukasz Bzdzion familiarises issues related to the market of biopharmaceuticals. More information on the potential of new pharmacology can be found on […]

Bioceltix at 22nd edition of Wall Street conference in Karpacz

Between May 25 and 27, the largest Poland-based meeting in of individual investors with entities related to the capital market in Eastern Europe was held. During the Wall Street conference, its speakers delivered 40 speeches that were heard by approximately 1,000 participants. During the conference, Łukasz Bzdzion – the President of Bioceltix – actively participated […]

Bioceltix testing equipment for isolated production line

At the beginning of May, specialists from Bioceltix – jointly with engineers from the Czech-based Block company – conducted functional tests within the framework of a MOCK-UP study. It employed a mock-up of a modular system of the isolated technological line for the production of animal allogeneic stem cells in line with the pharmaceutical standard. […]

Bioceltix changing standards of veterinary therapy

A stem-cell therapy carried out in the allogeneic setting, standing for one donor-many recipients, enables the manufacture of a batch of the medicine from its starting material obtained from one properly evaluated donor and with no necessity for every-time acquisition of biological material from a given patient in order to obtain their own cells for […]

Public money drives a white and red technological breakthrough

One of last year’s beneficiaries of Sub-measure 1.1.1 of the Intelligent Development Operational Program 2014-2020 is Bioceltix, a Wroclaw biotechnology start-up, implementing on the world market veterinary biopharmaceuticals based on mesenchymal stem cells (MSC). The technology developed by the Bioceltix team allows the use of allogeneic stem cells in the therapy without the need to […]

Bringing Bioceltix facilities up to GMP standards

Our production and quality control facilities are being upgraded to cGMP standards. More equipment designed for quality control of stem cell-based biopharmaceutical will be arriving over the coming weeks. The first devices have already been installed.

Bioceltix signs a contract with BLOCK, a Czech company

We have concluded a contract with the Czech company BLOCK for a cGMP-compliant modular cell production system for clinical applications, to be installed at our laboratory. This highest quality equipment for the isolated production line meets cGMP requirements, ensuring superior operation costs and expenditure effectiveness when compared to the classic “clean room” set up. By […]

Bioceltix personnel training in Valencia

Bioceltix staff visited Spain for almost a week in order to finalise an equipment order for our laboratory. During these few days, we explored the innovative technological solutions available on the market and learned how to operate the new piece of equipment which will soon be installed also at our facility. Throughout the stay, our […]

The Bioceltix team is growing!

The Bioceltix team is developing its technology, upgrading its workspace to GMP standards and expanding its team. Our specialists were joined by Tatiana Włach, tasked with financial control in Bioceltix. Welcome aboard!

Bioceltix selects a supplier of isolated production line equipment

Bioceltix has selected a supplier of isolated production line equipment. The contract has been awarded to the Czech company – BLOCK. The tender procedure included the supply of pharmaceutical-standard cell culture equipment for the Bioceltix laboratory. The high quality, cGMP-compliant equipment will not only guarantee safety, but also allow us to produce biopharmaceuticals based on […]

The upgrading process of our laboratory has commenced

Our Research and Development Centre and the cGMP-compliant manufacturing facility are located at EIT+, which is one of the most comprehensive research infrastructures in this part of Europe. The upgrading of our laboratory, intended to adjust the workspace to GMP requirements, commenced in February. In the next few months, state-of-the-art equipment will be delivered to […]

Bioceltix at the “Gospodarcze Otwarcie Roku” conference

We wouldn’t dare miss the annual “Gospodarcze Otwarcie Roku” (Business Opening of the Year) conference on 21 February 2018. The meeting allows Polish entrepreneurs and financial experts to share their perspectives on forecasts, threats and opportunities for our country, Europe and the world. The topics discussed during this edition included the financing opportunities and investment […]

Meet our Partners

We are a team is dedicated to the constant search for new biotechnology solutions. We create top-of-the-line stem cell-based pharmaceuticals for veterinary use and cooperate with prominent scientists in state-of-the-art laboratories in common pursuit of new technologies. We work together with the Wrocław Research Centre EIT+ – a Polish research and development organisation that develops […]

Bioceltix is implementing a project co-financed by EU funds

Bioceltix is implementing the project entitled “The production of adipose tissue-derived allogeneic mesenchymal stem cells as compliant with the requirements of Good Manufacturing Practice – an active substance for the investigational medicinal product for advanced-therapy veterinary use, intended for clinical trials in the treatment of degenerative changes of joints and dysplasia in dogs”, co-financed by […]

Bioceltix is implementing a project co-financed by EU funds

Bioceltix is implementing the project entitled “The production of adipose tissue-derived allogeneic mesenchymal stem cells as compliant with the requirements of Good Manufacturing Practice – an active substance for the investigational medicinal product for advanced-therapy veterinary use, intended for clinical trials in the treatment of degenerative changes of joints and dysplasia in dogs”, co-financed by […]

The EMA Scientific Advice procedure

A consultation process through the Scientific Advice procedure has commenced. Our Research and Development Team has prepared questions regarding the production safety of a medicinal product for veterinary use based on allogeneic stem cells isolated from canine adipose tissue. The EMA opinion on the query will be presented this October at the earliest. Within the […]

Pracelo enters into a dialogue with the European Medicines Agency

Pracelo has entered into an official dialogue with the European Medicines Agency. On 20 March 2017, an official “pre-submission” meeting took place between the representatives of Pracelo and the European Medicines Agency (EMA). The meeting covered the regulatory questions pertaining to the registration of a medicinal product for veterinary use based on mesenchymal allogeneic stem […]

Project launched within the 1/1.1.1./2016 “Fast Track” competition

On 02 March 2017, Pracelo signed an agreement on the co-financing for the implementation of the project entitled: “The production of adipose tissue-derived allogeneic mesenchymal stem cells as compliant with the requirements of Good Manufacturing Practice – an active substance for the investigational medicinal product for advanced-therapy veterinary use, intended for clinical trials in the […]

Pracelo assigned SME status by the EMA

We are pleased to announce that our application for the SME status had been approved by the European Medicines Agency, which means that Pracelo was registered as an SME with the EMA on 10 February 2017.

Pracelo recommended for the “Fast Track”

We are pleased to announce that Pracelo has been recommended for co-financing within the Smart Growth Operational Programme 2014-2020, Sub-Measure 1.1.1 Industrial research and development work implemented by enterprises, under the auspices of Narodowe Centrum Badań i Rozwoju (NCBiR) [The National Centre for Research and Development]. Of all the 369 applications submitted for the competition, […]

Pracelo applies for the SME status to the European Medicines Agency

The Company’s Management Board has submitted an application to the European Medicines Agency for assigning SME status to Pracelo Sp. z o.o. The SME status will contribute to a considerable reduction of expenses related to further scientific consultations within the Scientific Advice procedure, as well as expenses associated with the pharmaceutical registration process.

Powered by  Zgodności ciasteczek z RODO
Przegląd prywatności

Ta strona korzysta z ciasteczek, aby zapewnić Ci najlepszą możliwą obsługę. Informacje o ciasteczkach są przechowywane w przeglądarce i wykonują funkcje takie jak rozpoznawanie Cię po powrocie na naszą stronę internetową i pomaganie naszemu zespołowi w zrozumieniu, które sekcje witryny są dla Ciebie najbardziej interesujące i przydatne.